About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200
Debt
Debt-to-Equity Ratio1.45%
Current Ratio5.20%
Quick Ratio5.15%
Price-To-Earnings
Trailing P/E Ratio573.25
Forward P/E Ratio-352.77
P/E GrowthN/A
Sales & Book Value
Annual Sales$507.67 million
Price / Sales11.33
Cash Flow$0.3743 per share
Price / Cash122.51
Book Value$3.36 per share
Price / Book13.65
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$-5,960,000.00
Net Margins-1.18%
Return on Equity-1.94%
Return on Assets-0.50%
Miscellaneous
Employees547
Outstanding Shares125,440,000
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals (NASDAQ:IONS) released its quarterly earnings data on Tuesday, February, 27th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.10. The business earned $172 million during the quarter, compared to analyst estimates of $126.38 million. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. Ionis Pharmaceuticals's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.33 earnings per share. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What price target have analysts set for IONS?
13 Wall Street analysts have issued 1 year price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $51.3333 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC) and GW Pharmaceuticals (GWPH).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)
- Dr. Brett P. Monia, Founder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine (Age 57)
- Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)
- Mr. Patrick R. O'Neil, Chief Compliance Officer, Sr. VP of Legal, Gen. Counsel and Corp. Sec. (Age 44)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64)
Has Ionis Pharmaceuticals been receiving favorable news coverage?
Media coverage about IONS stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a news impact score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 44.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $45.86.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $5.58 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Ionis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.3333, suggesting that the stock has a possible upside of 11.93%. The high price target for IONS is $65.00 and the low price target for IONS is $18.00. There are currently 2 sell ratings, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Hold | Hold | Hold | Hold |
Consensus Rating Score: | 2.31 | 2.31 | 2.31 | 2.29 |
Ratings Breakdown: | 2 Sell Rating(s) 5 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s) | 2 Sell Rating(s) 5 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s) | 2 Sell Rating(s) 5 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s) | 2 Sell Rating(s) 6 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $51.3333 | $51.3333 | $50.9167 | $49.6154 |
Price Target Upside: | 11.93% upside | 0.27% downside | 6.90% downside | 18.90% downside |
Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Ionis Pharmaceuticals (NASDAQ:IONS) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 90.91%
Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/17/2018 | Stanley T Crooke | Chairman | Sell | 13,962 | $44.40 | $619,912.80 | 56,714 | |
3/29/2018 | Joseph Klein III | Director | Sell | 2,000 | $46.15 | $92,300.00 | 11,939 | |
3/15/2018 | Joseph Klein III | Director | Sell | 2,000 | $51.13 | $102,260.00 | | |
3/12/2018 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | 15,452 | |
2/28/2018 | Joseph Klein III | Director | Sell | 3,000 | $51.91 | $155,730.00 | 10,839 | |
2/15/2018 | Joseph Klein III | Director | Sell | 3,000 | $48.99 | $146,970.00 | 11,339 | |
2/1/2018 | C Frank Bennett | SVP | Sell | 12,500 | $52.50 | $656,250.00 | | |
1/30/2018 | Joseph Klein III | Director | Sell | 3,000 | $52.86 | $158,580.00 | | |
1/29/2018 | Patrick R O'neil | SVP | Sell | 355 | $55.00 | $19,525.00 | 14,507 | |
1/29/2018 | Stanley T Crooke | Chairman | Sell | 11,000 | $54.12 | $595,320.00 | | |
1/25/2018 | Patrick R O'neil | SVP | Sell | 645 | $55.00 | $35,475.00 | 15,097 | |
1/16/2018 | B Lynne Parshall | Director | Sell | 5,986 | $51.76 | $309,835.36 | 44,166 | |
1/16/2018 | Brett P Monia | COO | Sell | 2,821 | $51.76 | $146,014.96 | 18,604 | |
1/16/2018 | C Frank Bennett | SVP | Sell | 2,696 | $51.76 | $139,544.96 | 21,810 | |
1/16/2018 | Elizabeth L Hougen | CFO | Sell | 2,724 | $51.76 | $140,994.24 | 17,224 | |
1/16/2018 | Sarah Boyce | Insider | Sell | 2,196 | $51.76 | $113,664.96 | 11,127 | |
1/15/2018 | Stanley T Crooke | Chairman | Sell | 16,549 | $51.76 | $856,576.24 | 67,626 | |
1/8/2018 | Stanley T Crooke | Chairman | Sell | 11,000 | $52.01 | $572,110.00 | 48,014 | |
1/3/2018 | Stanley T Crooke | Chairman | Sell | 22,000 | $50.01 | $1,100,220.00 | 58,014 | |
1/2/2018 | Brett P Monia | SVP | Sell | 163 | $50.00 | $8,150.00 | 11,782 | |
12/29/2017 | Joseph Klein III | Director | Sell | 3,000 | $50.56 | $151,680.00 | | |
12/29/2017 | Joseph Klein III | Director | Sell | 3,000 | $50.56 | $151,680.00 | 12,939 | |
12/15/2017 | Elizabeth L Hougen | SVP | Sell | 5,000 | $52.55 | $262,750.00 | 15,392 | |
12/15/2017 | Joseph Klein III | Director | Sell | 3,000 | $51.69 | $155,070.00 | 12,939 | |
12/4/2017 | Elizabeth L Hougen | SVP | Sell | 4,000 | $57.00 | $228,000.00 | 14,392 | |
12/1/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.50 | $55,500.00 | 11,433 | |
11/30/2017 | Joseph Klein III | Director | Sell | 3,000 | $53.55 | $160,650.00 | 12,939 | |
11/29/2017 | Elizabeth L Hougen | SVP | Sell | 6,000 | $53.02 | $318,120.00 | 16,392 | |
11/16/2017 | Elizabeth L Hougen | SVP | Sell | 7,000 | $54.35 | $380,450.00 | 17,392 | |
11/15/2017 | Joseph Klein III | Director | Sell | 2,250 | $53.56 | $120,510.00 | 9,377 | |
11/13/2017 | Joseph Klein III | Director | Sell | 3,000 | $55.39 | $166,170.00 | 7,127 | |
11/1/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $58.35 | $58,350.00 | 11,433 | |
10/18/2017 | B Lynne Parshall | COO | Sell | 16,118 | $65.00 | $1,047,670.00 | 33,526 | |
10/18/2017 | C Frank Bennett | SVP | Sell | 12,250 | $65.00 | $796,250.00 | 27,291 | |
10/13/2017 | Richard S Geary | SVP | Sell | 8,268 | $60.00 | $496,080.00 | | |
10/13/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $59.46 | $981,090.00 | | |
10/5/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | | |
10/4/2017 | Stanley T Crooke | Chairman | Sell | 27,500 | $52.89 | $1,454,475.00 | | |
10/2/2017 | Stanley T Crooke | CEO | Sell | 15,000 | $52.00 | $780,000.00 | 43,014 | |
9/6/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | 10,633 | |
7/24/2017 | C Frank Bennett | SVP | Sell | 10,000 | $59.29 | $592,900.00 | 25,041 | |
7/20/2017 | Stanley T Crooke | Chairman | Sell | 11,000 | $55.35 | $608,850.00 | 48,014 | |
7/19/2017 | Ionis Pharmaceuticals Inc | Major Shareholder | Buy | 3,125,000 | $8.00 | $25,000,000.00 | 28,884,540 | |
7/17/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.45 | $865,425.00 | 53,014 | |
7/3/2017 | Brett P Monia | SVP | Sell | 309 | $51.35 | $15,867.15 | 11,935 | |
7/3/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.10 | $859,650.00 | 51,476 | |
6/1/2017 | Patrick R O'neil | SVP | Sell | 70 | $48.00 | $3,360.00 | 10,369 | |
5/1/2017 | Patrick R O'neil | SVP | Sell | 650 | $48.75 | $31,687.50 | 10,299 | |
4/25/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $47.81 | $788,865.00 | 53,014 | |
4/24/2017 | Patrick R O'neil | SVP | Sell | 500 | $45.00 | $22,500.00 | 10,523 | |
4/19/2017 | Stanley T Crooke | Chairman | Sell | 5,500 | $43.25 | $237,875.00 | 43,014 | |
4/13/2017 | Stanley T Crooke | Chairman | Sell | 22,000 | $40.69 | $895,180.00 | 48,014 | |
4/12/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $40.07 | $40,070.00 | 10,449 | |
3/3/2017 | C Frank Bennett | SVP | Sell | 5,000 | $55.00 | $275,000.00 | 19,788 | |
3/1/2017 | B Lynne Parshall | COO | Sell | 4,625 | $49.26 | $227,827.50 | 30,276 | |
3/1/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $49.29 | $73,935.00 | 12,949 | |
2/6/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | 12,449 | |
1/17/2017 | B Lynne Parshall | COO | Sell | 7,246 | $46.29 | $335,417.34 | 19,459 | |
1/17/2017 | Brett P Monia | SVP | Sell | 2,502 | $46.29 | $115,817.58 | 9,287 | |
1/17/2017 | Elizabeth L Hougen | CFO | Sell | 2,273 | $46.29 | $105,217.17 | 7,059 | |
1/17/2017 | Sarah Boyce | Insider | Sell | 1,361 | $46.29 | $63,000.69 | 5,318 | |
1/17/2017 | Stanley T Crooke | CEO | Sell | 15,382 | $46.29 | $712,032.78 | 30,576 | |
1/10/2017 | Stanley T Crooke | Chairman | Sell | 13,200 | $49.25 | $650,100.00 | 37,029 | |
1/4/2017 | Stanley T Crooke | Chairman | Sell | 18,700 | $48.89 | $914,243.00 | 30,029 | |
1/3/2017 | Brett P Monia | SVP | Sell | 309 | $48.60 | $15,017.40 | 8,181 | |
12/20/2016 | Brett P Monia | SVP | Sell | 130 | $52.48 | $6,822.40 | 7,872 | |
12/15/2016 | B Lynne Parshall | COO | Sell | 4,000 | $50.00 | $200,000.00 | 16,693 | |
12/5/2016 | Elizabeth L Hougen | CFO | Sell | 2,500 | $46.05 | $115,125.00 | 9,048 | |
12/5/2016 | Patrick R O'neil | SVP | Sell | 350 | $45.00 | $15,750.00 | 9,876 | |
12/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $42.23 | $527,875.00 | 23,693 | |
11/14/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | 9,720 | |
11/11/2016 | Elizabeth L Hougen | SVP | Sell | 5,000 | $39.75 | $198,750.00 | 9,048 | |
11/7/2016 | C Frank Bennett | SVP | Sell | 5,000 | $34.00 | $170,000.00 | 15,803 | |
10/5/2016 | Stanley T Crooke | Chairman | Sell | 11,000 | $36.61 | $402,710.00 | 35,029 | |
9/27/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $36.02 | $792,440.00 | 45,029 | |
9/21/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $35.50 | $781,000.00 | 45,029 | |
9/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $29.88 | $373,500.00 | 25,558 | |
5/31/2016 | Frederick T Muto | Director | Sell | 12,500 | $22.31 | $278,875.00 | 15,043 | |
4/6/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | 10,124 | |
4/6/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $46.13 | $507,430.00 | 30,029 | |
3/31/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $40.74 | $448,140.00 | 30,029 | |
3/23/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.40 | $45,400.00 | 10,124 | |
1/19/2016 | B Lynne Parshall | COO | Sell | 5,192 | $41.46 | $215,260.32 | 16,290 | |
1/19/2016 | C Frank Bennett | SVP | Sell | 2,110 | $41.46 | $87,480.60 | 10,590 | |
1/19/2016 | Elizabeth L. Hougen | CFO | Sell | 1,899 | $41.46 | $78,732.54 | 6,331 | |
1/19/2016 | Sarah Boyce | insider | Sell | 872 | $41.46 | $36,153.12 | 1,735 | |
1/19/2016 | Stanley T. Crooke | CEO | Sell | 13,401 | $41.46 | $555,605.46 | 25,029 | |
1/5/2016 | Stanley T. Crooke | CEO | Sell | 5,500 | $62.10 | $341,550.00 | 14,642 | |
1/4/2016 | B Lynne Parshall | COO | Sell | 809 | $61.05 | $49,389.45 | 8,215 | |
1/4/2016 | Brett P. Monia | SVP | Sell | 127 | $61.00 | $7,747.00 | 4,358 | |
1/4/2016 | Stanley T. Crooke | CEO | Sell | 11,000 | $61.05 | $671,550.00 | 14,642 | |
12/16/2015 | C Frank Bennett | SVP | Sell | 7,909 | $57.41 | $454,055.69 | 7,316 | |
12/1/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $61.50 | $61,500.00 | 6,259 | |
11/11/2015 | Joseph Klein III | Director | Sell | 6,875 | $64.18 | $441,237.50 | 5,543 | |
11/10/2015 | C Frank Bennett | SVP | Sell | 5,000 | $64.00 | $320,000.00 | 7,316 | |
11/6/2015 | C Frank Bennett | SVP | Sell | 5,000 | $56.00 | $280,000.00 | 7,316 | |
11/3/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $51.95 | $51,950.00 | 6,259 | |
10/23/2015 | Stanley T. Crooke | CEO | Sell | 44,000 | $43.85 | $1,929,400.00 | 14,642 | |
10/2/2015 | B Lynne Parshall | COO | Sell | 12,436 | $40.75 | $506,767.00 | 8,143 | |
7/6/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.01 | $354,488.18 | | |
7/6/2015 | Stanley T Crooke | CEO | Sell | 5,000 | $57.01 | $285,050.00 | | |
7/1/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.56 | $357,908.08 | | |
7/1/2015 | Stanley T Crooke | CEO | Sell | 6,175 | $57.56 | $355,433.00 | | |
6/8/2015 | Brett P Monia | SVP | Sell | 7,600 | $66.22 | $503,272.00 | | |
4/7/2015 | B Lynne Parshall | COO | Sell | 5,565 | $63.07 | $350,984.55 | | |
4/7/2015 | Stanley T Crooke | CEO | Sell | 22,377 | $63.07 | $1,411,317.39 | | |
3/24/2015 | C Frank Bennett | SVP | Sell | 15,000 | $70.61 | $1,059,150.00 | | |
3/19/2015 | Elizabeth L Hougen | CFO | Sell | 10,000 | $73.33 | $733,300.00 | | |
3/19/2015 | Patrick R O'neil | SVP | Sell | 30,525 | $74.85 | $2,284,796.25 | | |
3/2/2015 | Joseph H Wender | Director | Sell | 7,000 | $65.97 | $461,790.00 | | |
1/27/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $72.93 | $802,230.00 | | |
1/16/2015 | B Lynne Parshall | COO | Sell | 4,093 | $67.96 | $278,160.28 | | |
1/16/2015 | Elizabeth L Hougen | CFO | Sell | 1,291 | $67.96 | $87,736.36 | | |
1/16/2015 | Richard S Geary | SVP | Sell | 1,543 | $67.96 | $104,862.28 | | |
1/16/2015 | Stanley T Crooke | CEO | Sell | 9,054 | $67.96 | $615,309.84 | | |
1/9/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $73.57 | $809,270.00 | | |
1/7/2015 | Stanley T Crooke | CEO | Sell | 22,000 | $67.04 | $1,474,880.00 | | |
1/2/2015 | B Lynne Parshall | COO | Sell | 11,200 | $62.12 | $695,744.00 | | |
1/2/2015 | Patrick R O'neil | SVP | Sell | 1,500 | $62.12 | $93,180.00 | | |
12/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $51.21 | $76,815.00 | | |
11/3/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | | |
10/30/2014 | B Lynne Parshall | COO | Sell | 11,071 | $45.12 | $499,523.52 | | |
10/23/2014 | Stanley T Crooke | CEO | Sell | 14,600 | $42.22 | $616,412.00 | | |
10/3/2014 | Stanley T Crooke | CEO | Sell | 36,000 | $38.52 | $1,386,720.00 | | |
10/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $38.04 | $57,060.00 | | |
10/1/2014 | Stanley T Crooke | CEO | Sell | 20,000 | $37.91 | $758,200.00 | | |
8/27/2014 | C Frank Bennett | SVP | Sell | 5,000 | $40.53 | $202,650.00 | | |
8/13/2014 | Stanley T Crooke | CEO | Sell | 15,500 | $35.45 | $549,475.00 | | |
8/12/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.00 | $52,500.00 | | |
8/1/2014 | Stanley T Crooke | CEO | Sell | 16,000 | $30.53 | $488,480.00 | | |
7/31/2014 | Brett P Monia | SVP | Sell | 79 | $31.50 | $2,488.50 | | |
7/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.33 | $52,995.00 | | |
7/1/2014 | Stanley T Crooke | CEO | Sell | 17,500 | $35.57 | $622,475.00 | | |
6/23/2014 | C Frank Bennett | SVP | Sell | 11,200 | $36.78 | $411,936.00 | | |
6/19/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $35.10 | $386,100.00 | | |
6/10/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $33.46 | $368,060.00 | | |
6/2/2014 | Frederick T Muto | Director | Sell | 10,000 | $28.59 | $285,900.00 | | |
4/2/2014 | Stanley Crooke | CEO | Sell | 8,800 | $43.65 | $384,120.00 | 6,941 | |
1/30/2014 | B Lynne Parshall | COO | Sell | 89,510 | $49.49 | $4,429,849.90 | 4,022 | |
1/24/2014 | Joseph Klein III | Director | Sell | 10,313 | $48.66 | $501,830.58 | 2,313 | |
1/22/2014 | Joseph Wender | Director | Sell | 10,000 | $50.98 | $509,800.00 | 31,135 | |
1/22/2014 | Richard Geary | SVP | Sell | 22,200 | $50.05 | $1,111,110.00 | 4,955 | |
1/16/2014 | B Lynne Parshall | COO | Sell | 1,641 | $47.08 | $77,258.28 | 4,022 | |
1/16/2014 | Stanley Crooke | CEO | Sell | 3,527 | $47.08 | $166,051.16 | 6,941 | |
1/8/2014 | Richard Geary | SVP | Sell | 15,000 | $40.45 | $606,750.00 | 3,610 | |
1/8/2014 | Stanley Crooke | CEO | Sell | 12,500 | $40.05 | $500,625.00 | 1,661 | |
1/2/2014 | Stanley Crooke | CEO | Sell | 31,500 | $39.35 | $1,239,525.00 | 1,661 | |
12/26/2013 | B Lynne Parshall | COO | Sell | 37,811 | $40.91 | $1,546,848.01 | 956 | |
12/24/2013 | B Lynne Parshall | COO | Sell | 70,000 | $41.49 | $2,904,300.00 | 956 | |
12/20/2013 | Joseph Wender | Director | Sell | 19,731 | $39.58 | $780,952.98 | 41,135 | |
12/5/2013 | C Frank Bennett | SVP | Sell | 10,000 | $39.92 | $399,200.00 | 2,866 | |
11/26/2013 | Joseph Wender | Director | Sell | 10,000 | $36.63 | $366,300.00 | 45,866 | |
9/20/2013 | B Lynne Parshall | COO | Sell | 90,000 | $35.43 | $3,188,700.00 | 956 | |
9/20/2013 | Brett Monia | SVP | Sell | 68,281 | $34.21 | $2,335,893.01 | 769 | |
9/20/2013 | Stanley Crooke | CEO | Sell | 58,740 | $35.19 | $2,067,060.60 | 1,661 | |
9/19/2013 | C Frank Bennett | SVP | Sell | 10,000 | $35.02 | $350,200.00 | 2,866 | |
9/11/2013 | B Lynne Parshall | COO | Sell | 63,505 | $31.04 | $1,971,195.20 | | |
9/9/2013 | C Frank Bennett | SVP | Sell | 10,000 | $30.23 | $302,300.00 | | |
9/4/2013 | Patrick R O'neil | SVP | Sell | 2,500 | $27.09 | $67,725.00 | | |
8/26/2013 | Brett Monia | SVP | Sell | 2,909 | $25.58 | $74,412.22 | 769 | |
8/9/2013 | Joseph Klein III | Director | Sell | 18,750 | $28.22 | $529,125.00 | 8,313 | |
7/23/2013 | Stanley T Crooke | COO | Sell | 11,500 | $30.00 | $345,000.00 | | |
7/22/2013 | Stanley T Crooke | CEO | Sell | 62,200 | $30.50 | $1,897,100.00 | | |
7/17/2013 | Stanley T Crooke | CEO | Sell | 49,300 | $33.12 | $1,632,816.00 | | |
7/12/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $31.75 | $2,857,500.00 | | |
7/11/2013 | Richard S Geary | SVP | Sell | 9,000 | $31.90 | $287,100.00 | | |
7/9/2013 | Richard S Geary | SVP | Sell | 66,163 | $30.03 | $1,986,874.89 | | |
7/9/2013 | Stanley T Crooke | CEO | Sell | 109,172 | $26.69 | $2,913,800.68 | | |
7/3/2013 | Richard S Geary | SVP | Sell | 5,000 | $29.02 | $145,100.00 | | |
7/1/2013 | Stanley T Crooke | CEO | Sell | 50,683 | $27.65 | $1,401,384.95 | | |
6/26/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $26.73 | $2,405,700.00 | | |
6/25/2013 | Richard S Geary | SVP | Sell | 47,049 | $26.20 | $1,232,683.80 | | |
6/20/2013 | Joseph H Wender | Director | Sell | 5,447 | $20.93 | $114,005.71 | | |
6/11/2013 | Brett P Monia | SVP | Sell | 9,375 | $23.76 | $222,750.00 | | |
5/30/2013 | Frederick T Muto | Director | Sell | 10,000 | $21.96 | $219,600.00 | | |
1/16/2013 | Stanley T Crooke | CEO | Sell | 1,460 | $14.00 | $20,440.00 | | |
(Data available from 1/1/2013 forward)
Ionis Pharmaceuticals (NASDAQ IONS) News Headlines
Source: |
|
Date | Headline |
---|
 | Ionis Pharmaceuticals (IONS) Chairman Sells $619,912.80 in Stock www.americanbankingnews.com - April 19 at 7:34 PM |
 | Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations finance.yahoo.com - April 19 at 5:24 PM |
 | Ionis Pharmaceuticals (IONS) Raised to Buy at Zacks Investment Research www.americanbankingnews.com - April 18 at 10:16 PM |
 | Jazz Pharmaceuticals: How It’s Positioned before 1Q18 finance.yahoo.com - April 18 at 5:31 PM |
 | Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases finance.yahoo.com - April 17 at 5:41 PM |
 | Ionis Pharmaceuticals (IONS) Expected to Announce Quarterly Sales of $159.81 Million www.americanbankingnews.com - April 16 at 1:52 AM |
 | Ionis Pharmaceuticals (IONS) Coverage Initiated at Sanford C. Bernstein www.americanbankingnews.com - April 15 at 3:59 PM |
 | Ionis Pharmaceuticals (IONS) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 15 at 10:59 AM |
 | Brokerages Anticipate Ionis Pharmaceuticals (IONS) Will Announce Earnings of -$0.11 Per Share www.americanbankingnews.com - April 14 at 11:20 PM |
 | Ionis Pharmaceuticals (IONS) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - April 14 at 8:37 PM |
 | Zacks Investment Research Downgrades Ionis Pharmaceuticals (IONS) to Hold www.americanbankingnews.com - April 12 at 11:21 PM |
 | Ionis Pharmaceuticals (IONS) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 12 at 10:23 AM |
 | Ionis Pharmaceuticals (IONS) PT Raised to $50.00 at Stifel Nicolaus www.americanbankingnews.com - April 11 at 11:52 PM |
 | Ionis Pharmaceuticals' (IONS) "Underperform" Rating Reiterated at Jefferies Group www.americanbankingnews.com - April 11 at 1:19 PM |
 | Ionis Pharma (IONS), AstraZeneca (AZN) Advance New Drug for NASH www.streetinsider.com - April 10 at 8:49 AM |
 | Why AveXis, Inc. Stock Is Soaring Today finance.yahoo.com - April 9 at 5:07 PM |
 | AstraZeneca licenses NASH candidate from Ionis Pharma seekingalpha.com - April 9 at 8:44 AM |
 | Ionis Pharmaceuticals (IONS) Upgraded to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 7 at 11:38 AM |
 | Ionis Pharmaceuticals (IONS) Given Buy Rating at Needham & Company LLC www.americanbankingnews.com - April 7 at 12:03 AM |
 | Ionis Pharmaceuticals (IONS) Lowered to Sell at BidaskClub www.americanbankingnews.com - April 5 at 12:30 AM |
 | BMO Capital Markets Raises Ionis Pharmaceuticals (IONS) Price Target to $65.00 www.americanbankingnews.com - April 1 at 9:47 AM |
 | Ionis Pharmaceuticals (IONS) Price Target Increased to $49.00 by Analysts at Morgan Stanley www.americanbankingnews.com - April 1 at 9:47 AM |
 | Ionis Pharmaceuticals (IONS) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 31 at 11:34 AM |
 | Analysts Expect Ionis Pharmaceuticals (IONS) Will Post Quarterly Sales of $159.81 Million www.americanbankingnews.com - March 31 at 4:38 AM |
 | Ionis Pharmaceuticals (IONS) Director Joseph Klein III Sells 2,000 Shares www.americanbankingnews.com - March 30 at 4:14 PM |
 | Pfizer Takes On Alnylam, Ionis With Rare Disease Treatment finance.yahoo.com - March 30 at 8:41 AM |
 | Ionis Pharmaceuticals’ Quarterly Revenue Trend finance.yahoo.com - March 29 at 8:47 AM |
 | Ionis Pharmaceuticals (IONS) Expected to Post Earnings of -$0.11 Per Share www.americanbankingnews.com - March 29 at 3:08 AM |
 | Ionis Pharmaceuticals’ Valuation as of March 27, 2018 finance.yahoo.com - March 28 at 5:07 PM |
 | ValuEngine Lowers Ionis Pharmaceuticals (IONS) to Sell www.americanbankingnews.com - March 28 at 11:55 AM |
 | Ionis Pharmaceuticals (IONS) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - March 28 at 10:55 AM |
 | Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis www.prnewswire.com - March 26 at 7:42 AM |
 | Akcea Convenes First FCS Global Connection Summit feeds.benzinga.com - March 26 at 7:42 AM |
 | Ionis Pharmaceuticals (IONS) Downgraded to D+ at TheStreet www.americanbankingnews.com - March 24 at 2:13 PM |
 | Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders finance.yahoo.com - March 23 at 8:40 AM |
 | Wired News - Ionis Pharma Granted Exclusive Global License to Akcea to Commercialize Inotersen for hATTR finance.yahoo.com - March 19 at 8:41 AM |
 | Insider Selling: Ionis Pharmaceuticals Inc (IONS) Director Sells 2,000 Shares of Stock www.americanbankingnews.com - March 16 at 8:36 PM |
 | Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping - Motley Fool www.fool.com - March 16 at 8:39 AM |
 | Ionis Pharma (IONS), Akcea Therapeutics (AKCA) Partner on Inotersen for hATTR; $150M Upfront to Ionis Paid in Stock - StreetInsider.com www.streetinsider.com - March 15 at 8:34 AM |
 | Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS) www.americanbankingnews.com - March 15 at 6:35 AM |
 | Patrick R. O'neil Sells 1,000 Shares of Ionis Pharmaceuticals Inc (IONS) Stock www.americanbankingnews.com - March 13 at 10:28 PM |
 | $159.81 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter www.americanbankingnews.com - March 13 at 2:40 AM |
 | Analysts Expect Ionis Pharmaceuticals Inc (IONS) Will Announce Earnings of -$0.11 Per Share www.americanbankingnews.com - March 11 at 8:35 PM |
 | Ionis Pharmaceuticals (IONS) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - March 11 at 6:02 AM |
 | BidaskClub Upgrades Ionis Pharmaceuticals (IONS) to Buy www.americanbankingnews.com - March 10 at 5:28 PM |
 | Ionis Pharmaceuticals (IONS) Lifted to Hold at Zacks Investment Research www.americanbankingnews.com - March 10 at 4:04 PM |
 | Ionis Is A Buy On RNA Platform Pipeline - Seeking Alpha seekingalpha.com - March 7 at 8:40 AM |
 | Ionis Pharmaceuticals Inc (IONS) Position Raised by Tocqueville Asset Management L.P. www.americanbankingnews.com - March 6 at 3:40 PM |
 | UBS Asset Management Americas Inc. Boosts Holdings in Ionis Pharmaceuticals Inc (IONS) www.americanbankingnews.com - March 6 at 3:15 PM |
 | Ionis Pharmaceuticals Inc (IONS) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 6 at 11:45 AM |
Ionis Pharmaceuticals (NASDAQ:IONS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ionis Pharmaceuticals (NASDAQ:IONS) Income Statement, Balance Sheet and Cash Flow Statement
Ionis Pharmaceuticals (NASDAQ IONS) Stock Chart for Thursday, April, 19, 2018
Loading chart…